EWTX
Edgewise Therapeutics, Inc.
$40.35
-1.25
(-3.00%)
Mkt Cap
4.34B
Volume
902,387
52W Range
12.3-48.4
Sector
Healthcare
Beta
0.28
EPS (TTM)
-1.66
P/E Ratio
-15.23
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.79M) | (133.81M) | (100.16M) | (67.64M) | (42.81M) | (17.05M) | (9.49M) |
| EPS | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 | -0.19 |
| Free Cash Flow | (143.82M) | (110.34M) | (97.69M) | (58.18M) | (34.17M) | (14.84M) | (9.35M) |
| FCF / Share | -1.40 | -1.19 | -1.53 | -1.09 | -0.69 | -0.30 | -0.19 |
| Operating CF | (143.82M) | (109.03M) | (91.95M) | (52.63M) | (33.51M) | (14.63M) | (9.17M) |
| Total Assets | 552.60M | 486.82M | 340.04M | 367.10M | 285.23M | 131.14M | 24.54M |
| Total Debt | 3.99M | 4.74M | 5.41M | 4.41M | 0 | 160.21M | 0 |
| Cash & Equiv | 61.15M | 41.67M | 86.10M | 21.99M | 15.57M | 104.92M | 23.65M |
| Book Value | 522.26M | 459.22M | 318.83M | 346.72M | 274.38M | (33.42M) | (16.85M) |
| Return on Equity | -0.32 | -0.29 | -0.31 | -0.20 | -0.16 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.01M) | (50.22M) | (40.67M) | (36.12M) | (40.80M) | (39.66M) | (34.13M) | (31.50M) | (28.52M) | (30.14M) | (25.71M) | (21.47M) |
| EPS | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 |
| Free Cash Flow | (42.80M) | (38.41M) | (34.87M) | (32.63M) | (37.91M) | (27.23M) | (27.89M) | (26.32M) | (28.89M) | (26.99M) | (22.52M) | (20.99M) |
| FCF / Share | -0.40 | -0.37 | -0.33 | -0.31 | -0.40 | -0.29 | -0.30 | -0.28 | -0.33 | -0.42 | -0.35 | -0.33 |
| Operating CF | (42.54M) | (38.59M) | (34.78M) | (32.58M) | (37.87M) | (26.96M) | (27.37M) | (26.10M) | (28.60M) | (26.83M) | (22.06M) | (20.23M) |
| Total Assets | 518.52M | 552.60M | 583.47M | 613.33M | 454.39M | 486.82M | 511.28M | 531.65M | 553.81M | 340.04M | 311.36M | 330.62M |
| Total Debt | 3.79M | 3.99M | 4.18M | 4.37M | 4.56M | 4.74M | 4.44M | 4.99M | 5.25M | 5.41M | 5.53M | 5.64M |
| Cash & Equiv | 33.21M | 61.15M | 46.00M | 43.40M | 49.92M | 41.67M | 44.81M | 43.48M | 30.26M | 86.10M | 32.96M | 31.81M |
| Book Value | 493.20M | 522.26M | 558.65M | 589.07M | 429.72M | 459.22M | 488.88M | 510.47M | 534.94M | 318.83M | 290.43M | 311.45M |
| Return on Equity | -0.10 | -0.10 | -0.07 | -0.06 | -0.09 | -0.09 | -0.07 | -0.06 | -0.05 | -0.09 | -0.09 | -0.07 |
EWTX News
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Edgewise shares slip after heart-disease drug trial data disappoints investors
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal